WO2004005535A2 - Pathogenicity proteins which can be used as targets for developing means for preventing and controlling bacterial infections - Google Patents

Pathogenicity proteins which can be used as targets for developing means for preventing and controlling bacterial infections Download PDF

Info

Publication number
WO2004005535A2
WO2004005535A2 PCT/EP2003/008209 EP0308209W WO2004005535A2 WO 2004005535 A2 WO2004005535 A2 WO 2004005535A2 EP 0308209 W EP0308209 W EP 0308209W WO 2004005535 A2 WO2004005535 A2 WO 2004005535A2
Authority
WO
WIPO (PCT)
Prior art keywords
virulence
pathogenicity
serum
nucleic acids
targets
Prior art date
Application number
PCT/EP2003/008209
Other languages
French (fr)
Other versions
WO2004005535A3 (en
Inventor
Sonia Escaich
Original Assignee
Mutabilis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2004518773A priority Critical patent/JP2006515155A/en
Application filed by Mutabilis filed Critical Mutabilis
Priority to US10/520,820 priority patent/US20060003393A1/en
Priority to DK03762684T priority patent/DK1523572T3/en
Priority to AU2003266246A priority patent/AU2003266246A1/en
Priority to EP03762684A priority patent/EP1523572B1/en
Priority to DE60320797T priority patent/DE60320797D1/en
Priority to CA002491847A priority patent/CA2491847A1/en
Publication of WO2004005535A2 publication Critical patent/WO2004005535A2/en
Publication of WO2004005535A3 publication Critical patent/WO2004005535A3/en
Priority to HK05109367A priority patent/HK1078902A1/en
Priority to US11/506,821 priority patent/US20070111229A1/en
Priority to AU2009201727A priority patent/AU2009201727A1/en
Priority to US12/729,630 priority patent/US20110236886A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms

Definitions

  • Pat ogenicity determinants which can be used as targets for developing means for preventing and controlling bacterial infections and/or systemic dissemination
  • the invention relates to pathogenicity determinants which can be used as targets for developing means for preventing and controlling bacterial infections and/or systemic disseminatio .
  • the invention provides a novel strategy, the aim of which is to specifically target pathogenic ba ⁇ teria without significantly altering their growth at their portal of entry into the host organism, where they are in a situation of commensalism.
  • pathogens are in particular the bacteria responsible for serious systemic infections, such as E . coli , in general Enterobacteria, Pseudomonas, Acinetobacter,
  • Moraxella and Neisseria and, for the gram positives, the bacteria of the genus Staphylococcus , Enter ⁇ COCCUS and Streptococcus .
  • the ability of bacteria to grow in human serum is due to different pathogenicity/virulence factors.
  • the physical barrier represented by the capsule, for access of complement to the bacterial membrane, the sialic acids of the capsule or of the 0 antigen which promote binding of factor H to c3b, and particular surface proteins such as PorA (Neisseria gonorrhoeae) , YadA ⁇ Yersinia pestis ) or protein M
  • Streptococcus pyogenes which bind factor H, all these factors preventing complement activation.
  • the lipopolysaccharide (LPS) of gram-negative bacteria is known to be a virulence factor, but the role of its various constituents on the resistance to serum has not been established for all bacterial species.
  • the 0 antigen is considered to be determinant (Burns S.M. Hull S.I. Infect I mun, 1998, Sept 66 (9) : 4244-53) ; in other studies, the 0 antigen is thought to be less determinant than the capsular antigens for resistance to serum (Russo T. et al., Infect Immun, 1995, Apr. 63 (4) : 1263-9) .
  • the importance of these factors on intestinal colonization is unknown.
  • the inventors have carried out a systematic analysis of mutants for inactivation of the genes required for surface polysaccharide synthesis, and have demonstrated, in Escherichia coli strains responsible for extra-intestinal infections, EXPEC, which genes are essential for the resistance to serum and the dissemination in the blood. These results are based on the study of the effect of mutations on virulence and intestinal colonization in an animal model.
  • the invention is therefore directed towards a novel methodology for defining the targets required for virulence, and not essential in vi tro, and thus providing novel anti- infectious agents specific for pathogenic bacteria, in particular for extra-intestinal E. coli, responsible for severe infections, as well as Gram positive strains, such as Streptococcus agalactiae . It is also directed towards the products of the genes required for resistance in the serum and virulence in vivo .
  • the pathogenic microorganism is in particular an EXPEC strain of E. coli or a Streptococcus agalactiae strain.
  • the virulence gene inactivation mutants used in this method fall within the scope of the invention.
  • Said mutants are characterized by the following properties : they are sensitive to serum; they are avirulent in mice model and they are able to colonize gut of axenic mice.
  • the invention is also directed towards the pathogenicity or virulence factors encoded by nucleic acids thus identified, which are necessary for the dissemination via the blood, but do not significantly affect the intestinal or mucosal colonization of pathogenic bacteria such as E. coli , Salmonella typhimurium, Klebsiella pneumoniae, Yersinia pestis, Serratia arcescens , Haemophilus influenzae, Pasteurella multocida , Vibrio cholerae , Pseudomonas aeruginosa , Acetinobacter , Moraxella catarrhalis , Burkholderia pseudomallei , Neisseria meningitidis , Neisseria gonorrhoeae , Campylobacter jejuni , Helicobacter pylori , Bacteroides fragilis , Clostridium acetobutylicum, Mycobacterium tuberculosis , Streptococcus py
  • the invention is in particular directed towards the pathogenicity or virulence targets encoded by isolated or purified nucleic acids having sequences SEQ ID Nos 16-30.
  • the pathogenicity or virulence targets of the invention are more particularly encoded by nucleic acids having sequences SEQ ID Nos 16, 17,19-30.
  • Said nucleic acids are cDNAs or RNAs. It particularly relates to pathogenicity or virulence targets encoded by nucleic acids of E. coli .
  • the pathogenicity or virulence targets are encoded by nucleic acids of Streptococcus agalactiae.
  • the invention is also directed towards the vectors comprising at least a nucleic acid coding for a pathologenicity or virulence target such as above defined and also the host cells containing at least one vector under the control of a suitable promoter.
  • the invention is also directed towards pathogenicity or virulence factors corresponding to isolated or purified polypeptides or peptides having one of the amino acid sequences SEQ ID Nos 1-15.
  • the antibodies which are ' capable of binding specifically to the peptides and polypeptides corresponding to said factors are also part of the invention.
  • nucleic acids and peptides or polypeptides constitute targets for identifying compounds with a specific inhibitory effect on the systemic dissemination of a bacterial infection, and not on mucosal colonization or, for enterobacteria, on intestinal colonization, which makes it possible to preserve the commensal flora and to avoid the selection of resistance to the compounds .
  • the invention is thus directed towards the method for inhibiting the proliferation of a pathogenic microorganism in serum, comprising the use of an effective amount of a compound capable of inhibiting the activity, or of reducing the amount, of a nucleic acid as defined above, or of a compound capable of inhibiting the activity of a polypeptide or of a peptide as defined above.
  • the compounds thus selected are used, in accordance with the invention, to produce medicinal products for inhibiting a bacterial infection, in particular an extra-intestinal infection in the case of enterobacteria .
  • the invention thus provides a novel strategy and novel means for preventing or treating systemic bacterial dissemination, bacteraemia and septicaemia.
  • Example 1 gene corresponding to SEQ ID N°23:
  • the general strategy based on a recombination system, consists in interrupting a gene, by allelic recombination, with a gene for selection (a gene for resistance to antibiotic in the present case) carried by a linear DNA fragment.
  • a plasmid is introduced into the bacterium (for example E. coli ) , so as to introduce, in trans, the proteins which will induce the recombination.
  • the plasmid carrying an ampicillin resistance gene is thermosensitive (30°C), which will make it possible to easily eliminate it after use in the bacterium.
  • the plasmid is introduced into the bacterium by electroporation. After electroporation, the ampicillin- resistant bacteria will be those which have integrated the plasmid, and will be selected. This step is entirely carried out at 30°C, the permissive temperature for the plasmid.
  • a PCR is carried out, on a matrix plasmid carrying the selection gene (chloramphenicol resistance) , using primers pg23Pl and pg23P2 of sequences SEQ ID No 31 and SEQ ID No 32, respectively, made up of two parts: in 3' : 20 bp homologous to the selection gene (chloramphenicol resistance) : PI or P2 in 5' : 40 bp homologous to the target gene (pg23) : HI or H2 pg23Pl: 5'
  • a DNA fragment consisting of the selection gene (CAT: Chloramphenicol Acetyl Transferase) flanked by the regions homologous to the target gene Hi and H2 is thus obtained.
  • the bacterium containing the plasmid is cultured in LB medium at 30 °C with shaking, in the presence of 100 mM ampicillin and of 1 mM L-arabinose so as to induce the recombination system.
  • the culture is stopped, and the bacteria are harvested and made electrocompetent .
  • the PCR product specific- for the target gene [pg23) is introduced into the bacterium by electroporation.
  • the bacteria are then cultured in a non- selective rich medium (SOC medium) at 37 °C with shaking for 2 hours, and then plated out onto selective LB agar medium. After 18 hours at 37 °C, only the bacteria which have integrated the gene for resistance to the antibiotic will have grown.
  • SOC medium non- selective rich medium
  • PCR reactions are carried out directly using colonies.
  • Three pairs of primers are used: a pair in which the primers FR1 and FR2 frame the target gene, and two pairs using a primer located inside the resistance cassette, the other primer being located either upstream or downstream of the target gene.
  • the colonies thus verified by PCR are successively re-isolated on selected medium, twice on non-selective medium and a final time on selective medium at 37°C. Finally, the selected bacteria are tested for sensitivity to ampicillin, which reflects the absence of the plasmid. Three clones are thus chosen for each type of mutant.
  • the serum used is of human origin.
  • growth was also effected for the wild-type strain (S26, clinical isolate of E. coli particularly resistant to serum and virulent in mice) and a strain, ECOR4, lacking a capsule and lipopolysaccharide (LPS) .
  • the growths were effected in triplicate and in two different sera.
  • the growths were effected in parallel in complemented and decomplemented (30 min at 56°C) serum in order to verify that the effect observed was due only to the lytic action of complement.
  • the mutant ⁇ pg23 exhibits considerable sensitivity to the serum: a difference from the wild-type strain of more than 2 log at 1 hour and of more than 4 log at 4 hours is in fact observed.
  • the results obtained in decomplemented serum and with the strain ECOR4 in serum indicate that the effect observed is indeed due to the bactericidal action of complement.
  • the wild-type mutated bacteria are isolated from the strain, stored at -80 °C, on an LB agar dish with or without antibiotic, and incubated at 37 °C for 18 hours.
  • a preculture is prepared in liquid medium. Using a 1/lOth dilution in 10 ml of LB, the culture is regrown at 37 °C with shaking for 2 hours. After culturing for 2 hours, the OD 60 o nm is measured and various dilutions are prepared in physiological saline, so as to obtain the desired inoculum.
  • the LD 50 corresponds to an inoculum of 5xl0 5 cfu/mouse and the LD 100 corresponds to an inoculum of 1x10 s cfu/mouse.
  • mice (6-week-old Balb/c) are given an intraperitoneal injection and the bacterial solution injected represents a volume of 100 ⁇ l. Five mice are used per dose.
  • S26 ⁇ pg23 4 inoculums were tested and the survival rate was measured after 24 and 48 hours post-injection.
  • the study was carried out in parallel with the wild-type strain, the LD 5 0 of which is 5xl0 5 cfu/mouse.
  • the mutant S26 ⁇ pg23, injected at a dose equal to 10 times the LDioo / causes no mortality, the mutation of the pg23 gene in the E. coli strain Kl S26 is therefore responsible for a considerable decrease in the virulence.
  • the entire experiment is carried out in a sterile environment, with sterile instruments, in an isolator, and the mice are given sterile food.
  • mice These are 6- to 8-week-old axenic female mice of the C3H/He J line.
  • the wild-type and mutated bacteria are isolated from the strain, stored at -80°C, on an LB agar dish with or without antibiotic, and incubated at 37 °C for 18 hours. After culturing the strain in liquid medium, various dilutions are prepared in physiological saline, so as to obtain an inoculum of 10 7 cfu/ml.
  • the bacterial inoculation is carried out orally. During the 24 hours preceding inoculation, the mice are deprived of water. They are then given a bacterial solution at IO 7 cfu/ml to drink for 4 hours. The volume of drink is measured at 0 and 4 hours, and, on average, a mouse absorbs 5 ml of this bacterial solution. The faeces are then sampled at various times, and a bacterial count is performed, taking the faeces up in physiological saline and plating out various dilutions on an LB agar dish with and without antibiotic. The results are given in table 1 herein below.
  • colonization in the intestine was stably established. No difference is observed between the wild-type strain and the mutant ⁇ pg23. The colonization is confirmed on the final day by removing the intestine and counting the bacteria after grinding of this organ.
  • the nucleic acid encoding the polypeptide is cloned into a prokaryotic expression vector such as pET-14b with an N- terminal poly-his tag, according to conventional cloning methods .
  • the recombinant plasmid is then used to transform the E . coli strain BL21.
  • the transformed cells are selected in the presence of ampicillin and the colonies are isolated. They are then cultured in the presence of IPTG in order to induce expression of the protein.
  • the clones producing the protein are cultured and the total proteins are extracted by cell lysis.
  • the recombinant protein is purified with a histidine tag affinity column, according to the manufacturer's protocol.
  • the protein thus obtained is purified and used in vi tro to measure its enzyme activity.
  • Example 2 serum sensitivity and LD 5Q determination of mutant strains in the mice model of infection
  • Said mutants were also compared to the wild type S26 E. coli strain for LD 5 o determination in the mice model of infection. As presented in Table 2 below, the number of colony forming unit (cfu) counted after culture for four hours in serum was higher in the wild type (wt) S26 strain than in mutants indicating that mutants were sensitive to serum killing.
  • mice lethal dose 50
  • mice completely avirulent as no dose killing 50% of mice could be reach with the mutants.
  • the bacteria colonizing the intestine of axenic mice after eight days were characterized to verify that they correspond to the mutant strains that were inoculated orally.
  • LPS inner core metabolism are not essential in E . coli strains for colonization, but are necessary for resistance to complement and virulence in vivo .
  • the present invention relates to novel mutant strain of Group B Streptococcus (GBS) ⁇ Streptococcus agalactiae) .
  • the identified targets correspond to gene sequence number 29 encoding a protein sequence number 14 involved in incorporation of D-alanine residues into the cell wall-associated lipoteichoic acids (LTAs) in Gram + bacteria.
  • the gene sequence number 29 is homologous to the dl tD gene found in other gram positive bacteria and is the last gene of the dlt operon.
  • the Gram + bacterial model used is the pathogenic strain S . agalactiae NEM316.
  • S . agalactiae is a bacterium commonly found in the human flora and is phylogeneticaly close to Gram + bacteria responsible for nosocomial septicemia.
  • the virulence of GBS mutants in the dlt operon is strongly impaired in mouse and newborn rat models.
  • the loss of virulence is presumably due to an increased sensitivity to antimicrobial cationic peptides, such as defensins, which are produced by numerous cells types in particular phagocytes.
  • mutant of S . agalactiae in which the dltD gene have been inactivated, demonstrates that the product of that gene is a good target for the development of inhibitors of virulence of S . agalactiae as well as against other Gram + pathogens. Construction of a DtlD mutant in wild type S . agalactiae NEM316:
  • a mutant in the dltD gene was constructed from S . agalactiae NEM316 strain by inserting, using double cross-over, a kanamycin resistance cassette.
  • DltD mutant of S. agalactiae NEM316 a promoterless and termina torless kanamycin resistance cassette aphA-3 within DNA segment internal to dltD were inserted in the same direction of transcription . This was done by ligation after digestion wi th appropriate enzymes, of PCR products obtained by using the primers of SEQ ID N° 33 and 34 respectively,
  • SEQ ID N°33 5 ' -CAGTGAATTCGCGTTGACGAAGGCAGG-3 '
  • SEQ ID N°34 5 ' -GACGGGTACCATACCTATCGTAGGTTG-3 '
  • primers of SEQ ID N° 35 and SEQ ID N°36 respectively, SEQ ID N°35 : 5 ' -AGTGGATCCACTACACAGGGCTTGATC-3 '
  • SEQ ID N°36 5 ' -GACCTGCAGCCCTTGATTATCCCTATCC-3 ' .
  • thermosensitive shuttle vector pG+host5 ⁇ aphA-3 (Biswas et al., 1993, J Bacteriol. 175:3628-3635) containing the kanamycin resistance cassette to generate pGl ⁇ EKaphA-3.
  • a 0.8 kb closely spaced dltD region BamHI-Pstl fragment was inserted into pGl ⁇ EKaphA-3 to generate pGl ⁇ EKaphA-3BP.
  • the resulting vector was introduced by electroporation into NEM316.
  • Transformants were selected on Todd-Hewitt (TH) agar plates containing 10 mg l -1 erythromycin at 30 °C. Allelic exchange was obtained at the non-permissive temperature (42°C) by homologous recombination using a two-step procedure described previously (Biswas et al . , 1993).
  • the sensitivity of wild type S . agalactiae NEM316 and DltD mutant to cationic antimicrobial peptides was measured by using a disk diffusion methods. The 2 strains were grown on blood agar plates and incubated for 18 hours at 37 °C. Each strain was tested using colistin (50 ⁇ g) and polymixin (10 ⁇ g) disks. Sensitivity . or resistance of NEM316 strain and the DltD mutant to each compound was determined by the size of the growth inhibition area around disk.
  • the DltD mutant exhibited an increased sensitivity to the cationic antimicrobial peptides colistin, and polymyxin B as shown in table 5.
  • mice Six week-old Balb/c were inoculated intravenously with 5 x IO 7 bacteria. At 2 days post infection,
  • FIG. 1 illustrates the results obtained with the DltD defective GBS mutant. The result demonstrates that the product of the dltD gene is necessary for virulence of GBS in mice.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention relates to a method for identifying and selecting a gene required for the proliferation in vivo of a pathogenic microorganism, comprising :- using a strain of the pathogenic microorganism,- generating mutants for inactivation in the genes encoding these factors,- determining the virulence of these mutants on an expiremental model of infection, and their effect on enteric colonization in an axenic mouse model, and- selecting the bacterial genes essential for resistance to serum in vitro, and essential, in the host, for dissemination in the serum.Application to the screening of compounds which inhibit the products of the genes identified, and to the inhibition in vitro of the proliferation of a pathogenic microorganism in serum.

Description

Pat ogenicity determinants which can be used as targets for developing means for preventing and controlling bacterial infections and/or systemic dissemination
The invention relates to pathogenicity determinants which can be used as targets for developing means for preventing and controlling bacterial infections and/or systemic disseminatio .
Current treatments for infectious diseases of bacterial origin are based on the inhibition of essential bacterial targets in vi tro using antibiotics. These targets are conserved in many bacterial species and make it possible to treat various types of infection. However, broad-spectrum antibiotics are active on the host's commensal flora, which promotes the acquisition and transfer of mechanisms of resistance to these antibiotics, hence a limiting of the ef ectiveness of current treatments with antibiotics. A need therefore exists for novel antibacterial treatments.
In this regard, the invention provides a novel strategy, the aim of which is to specifically target pathogenic baσteria without significantly altering their growth at their portal of entry into the host organism, where they are in a situation of commensalism. These pathogens are in particular the bacteria responsible for serious systemic infections, such as E . coli , in general Enterobacteria, Pseudomonas, Acinetobacter,
Moraxella and Neisseria and, for the gram positives, the bacteria of the genus Staphylococcus , EnterΌ COCCUS and Streptococcus .
It is known, specifically, that the bacteria responsible for serious infections are capable of growth in the presence of serum and are resistant to the bactericidal action of complement. This resistance allows dissemination of the infection, via the blood, to the various tissues of the host's body.
The ability of bacteria to grow in human serum is due to different pathogenicity/virulence factors. Among those frequently cited, mention will be made of the physical barrier, represented by the capsule, for access of complement to the bacterial membrane, the sialic acids of the capsule or of the 0 antigen which promote binding of factor H to c3b, and particular surface proteins such as PorA (Neisseria gonorrhoeae) , YadA { Yersinia pestis ) or protein M
( Streptococcus pyogenes) , which bind factor H, all these factors preventing complement activation.
Other proteins expressed or bound by the pathogens have proved to be important for resistance to complement and cause cleavage of complement factors or inhibit their binding to the surface of the bacterium (Rautemaa R. ; Meri S., Microbes and Infection 1999, 1:785:794).
The lipopolysaccharide (LPS) of gram-negative bacteria is known to be a virulence factor, but the role of its various constituents on the resistance to serum has not been established for all bacterial species. For example, in some studies in E. coli , the 0 antigen is considered to be determinant (Burns S.M. Hull S.I. Infect I mun, 1998, Sept 66 (9) : 4244-53) ; in other studies, the 0 antigen is thought to be less determinant than the capsular antigens for resistance to serum (Russo T. et al., Infect Immun, 1995, Apr. 63 (4) : 1263-9) . Furthermore, the importance of these factors on intestinal colonization is unknown. The inventors have carried out a systematic analysis of mutants for inactivation of the genes required for surface polysaccharide synthesis, and have demonstrated, in Escherichia coli strains responsible for extra-intestinal infections, EXPEC, which genes are essential for the resistance to serum and the dissemination in the blood. These results are based on the study of the effect of mutations on virulence and intestinal colonization in an animal model.
The invention is therefore directed towards a novel methodology for defining the targets required for virulence, and not essential in vi tro, and thus providing novel anti- infectious agents specific for pathogenic bacteria, in particular for extra-intestinal E. coli, responsible for severe infections, as well as Gram positive strains, such as Streptococcus agalactiae . It is also directed towards the products of the genes required for resistance in the serum and virulence in vivo .
The method of the invention for identifying and selecting a gene required for the proliferation in vivo of a pathogenic microorganism is characterized in that it comprises:
• using a strain of the pathogenic microorganism,
• generating mutants for inactivation in the genes encoding the virulence factors,
• determining the virulence of these mutants on an experimental model of infection and their effect on enteric colonization in an axenic mouse model, and
• selecting the bacterial genes essential for resistance to serum in vitro and essential, in the host, for dissemination in the blood. The pathogenic microorganism is in particular an EXPEC strain of E. coli or a Streptococcus agalactiae strain.
The virulence gene inactivation mutants used in this method fall within the scope of the invention.
Said mutants are characterized by the following properties : they are sensitive to serum; they are avirulent in mice model and they are able to colonize gut of axenic mice.
The invention is also directed towards the pathogenicity or virulence factors encoded by nucleic acids thus identified, which are necessary for the dissemination via the blood, but do not significantly affect the intestinal or mucosal colonization of pathogenic bacteria such as E. coli , Salmonella typhimurium, Klebsiella pneumoniae, Yersinia pestis, Serratia arcescens , Haemophilus influenzae, Pasteurella multocida , Vibrio cholerae , Pseudomonas aeruginosa , Acetinobacter , Moraxella catarrhalis , Burkholderia pseudomallei , Neisseria meningitidis , Neisseria gonorrhoeae , Campylobacter jejuni , Helicobacter pylori , Bacteroides fragilis , Clostridium acetobutylicum, Mycobacterium tuberculosis , Streptococcus pyogenes, Streptococcus agalactiae, Staphyloccus aureus and Enterococcus .
The invention is in particular directed towards the pathogenicity or virulence targets encoded by isolated or purified nucleic acids having sequences SEQ ID Nos 16-30.
The pathogenicity or virulence targets of the invention are more particularly encoded by nucleic acids having sequences SEQ ID Nos 16, 17,19-30. Said nucleic acids are cDNAs or RNAs. It particularly relates to pathogenicity or virulence targets encoded by nucleic acids of E. coli .
In another embodiment of the invention, the pathogenicity or virulence targets are encoded by nucleic acids of Streptococcus agalactiae.
The invention is also directed towards the vectors comprising at least a nucleic acid coding for a pathologenicity or virulence target such as above defined and also the host cells containing at least one vector under the control of a suitable promoter.
The invention is also directed towards pathogenicity or virulence factors corresponding to isolated or purified polypeptides or peptides having one of the amino acid sequences SEQ ID Nos 1-15.
It more particularly relates to pathogenicity or virulence factors corresponding to isolated or purified polypeptides or peptides having the amino acid sequences SEQ ID Nos 1,2,4-15.
The antibodies which are 'capable of binding specifically to the peptides and polypeptides corresponding to said factors are also part of the invention.
These nucleic acids and peptides or polypeptides constitute targets for identifying compounds with a specific inhibitory effect on the systemic dissemination of a bacterial infection, and not on mucosal colonization or, for enterobacteria, on intestinal colonization, which makes it possible to preserve the commensal flora and to avoid the selection of resistance to the compounds . The invention is thus directed towards the method for inhibiting the proliferation of a pathogenic microorganism in serum, comprising the use of an effective amount of a compound capable of inhibiting the activity, or of reducing the amount, of a nucleic acid as defined above, or of a compound capable of inhibiting the activity of a polypeptide or of a peptide as defined above.
It is also directed towards a method for screening compounds capable of inhibiting the expression of these nucleic acids or of the corresponding polypeptides and peptides, comprising bringing them into contact with the test compound, demonstrating the possible effect of the compound on their activity, and selecting the active compounds.
It is also directed towards a method for screening compounds capable of inhibiting the biochemical and/or enzyme activity of the polypeptides and peptides expressed by said nucleic acids .
The compounds thus selected are used, in accordance with the invention, to produce medicinal products for inhibiting a bacterial infection, in particular an extra-intestinal infection in the case of enterobacteria .
The invention thus provides a novel strategy and novel means for preventing or treating systemic bacterial dissemination, bacteraemia and septicaemia.
Other characteristics and advantages of the invention will be given in the following examples, with reference to Figures 1 to 3 and tables 1 to 5, said figures representing, respectively, Figure 1, the growth of S26 and of the mutant pg23 in serum,
Figure 2, the growth of S26 and of the mutant pg23 in decomplemented serum, and - Figure 3, the virulence of the DltD mutant of S . agalactiae .
Example 1 : gene corresponding to SEQ ID N°23:
1- Inactivation of the gene of interest
The general strategy, based on a recombination system, consists in interrupting a gene, by allelic recombination, with a gene for selection (a gene for resistance to antibiotic in the present case) carried by a linear DNA fragment.
Initially, a plasmid is introduced into the bacterium (for example E. coli ) , so as to introduce, in trans, the proteins which will induce the recombination. The plasmid carrying an ampicillin resistance gene is thermosensitive (30°C), which will make it possible to easily eliminate it after use in the bacterium.
The plasmid is introduced into the bacterium by electroporation. After electroporation, the ampicillin- resistant bacteria will be those which have integrated the plasmid, and will be selected. This step is entirely carried out at 30°C, the permissive temperature for the plasmid.
Synthesis of the PCR fragment specific for the target gene [pg23)
A PCR is carried out, on a matrix plasmid carrying the selection gene (chloramphenicol resistance) , using primers pg23Pl and pg23P2 of sequences SEQ ID No 31 and SEQ ID No 32, respectively, made up of two parts: in 3' : 20 bp homologous to the selection gene (chloramphenicol resistance) : PI or P2 in 5' : 40 bp homologous to the target gene (pg23) : HI or H2 pg23Pl: 5'
TCGTGCAGGCCAACCTGCACAACAGAGTGATTTGATTAACGTGTAGGCTGGAGCTGCTTC
3'
HI PI
Pg23P2: 5'
CAGGGTGCTGGCGCTCACCATTTCCGGAGACAGCTTAGACACATATGAATATCCTCCTTA
31
H2 P2
A DNA fragment consisting of the selection gene (CAT: Chloramphenicol Acetyl Transferase) flanked by the regions homologous to the target gene Hi and H2 is thus obtained.
Step for inactivation of the target gene
The bacterium containing the plasmid is cultured in LB medium at 30 °C with shaking, in the presence of 100 mM ampicillin and of 1 mM L-arabinose so as to induce the recombination system. When the bacteria are in the exponential growth phase (OD60onm=0.5) , the culture is stopped, and the bacteria are harvested and made electrocompetent . The PCR product specific- for the target gene [pg23) is introduced into the bacterium by electroporation. The bacteria are then cultured in a non- selective rich medium (SOC medium) at 37 °C with shaking for 2 hours, and then plated out onto selective LB agar medium. After 18 hours at 37 °C, only the bacteria which have integrated the gene for resistance to the antibiotic will have grown.
Verification of the insertion of the resistance cassette
In order to verify the insertion of the resistance cassette, PCR reactions are carried out directly using colonies. Three pairs of primers are used: a pair in which the primers FR1 and FR2 frame the target gene, and two pairs using a primer located inside the resistance cassette, the other primer being located either upstream or downstream of the target gene.
Isolation of the mutated bacteria and elimination of the plasmid
The colonies thus verified by PCR are successively re-isolated on selected medium, twice on non-selective medium and a final time on selective medium at 37°C. Finally, the selected bacteria are tested for sensitivity to ampicillin, which reflects the absence of the plasmid. Three clones are thus chosen for each type of mutant.
2 - Test for the mutant with respect to resistance to the bactericidal activity of serum
The serum used is of human origin. In each experiment, growth was also effected for the wild-type strain (S26, clinical isolate of E. coli particularly resistant to serum and virulent in mice) and a strain, ECOR4, lacking a capsule and lipopolysaccharide (LPS) . The growths were effected in triplicate and in two different sera. The growths were effected in parallel in complemented and decomplemented (30 min at 56°C) serum in order to verify that the effect observed was due only to the lytic action of complement.
Using a preculture of two hours in RPMI reference minimum medium, the bacteria are brought into contact with 100% serum, at a starting inoculum of 104cfu/ml. Counts are then performed at times 0, 1 and 4 hours, by plating various dilutions out on LB agar medium in the presence or absence of antibiotic. After 18 hours at 37 °C, the bacteria are counted and a growth curve is produced from the results obtained. These results are given in Figures 1 and 2.
In this example, the mutant Δpg23 exhibits considerable sensitivity to the serum: a difference from the wild-type strain of more than 2 log at 1 hour and of more than 4 log at 4 hours is in fact observed. In addition, the results obtained in decomplemented serum and with the strain ECOR4 in serum indicate that the effect observed is indeed due to the bactericidal action of complement.
3 - Study of the virulence in a mouse animal model
Preparation of the inoculum The wild-type mutated bacteria are isolated from the strain, stored at -80 °C, on an LB agar dish with or without antibiotic, and incubated at 37 °C for 18 hours. A preculture is prepared in liquid medium. Using a 1/lOth dilution in 10 ml of LB, the culture is regrown at 37 °C with shaking for 2 hours. After culturing for 2 hours, the OD60onm is measured and various dilutions are prepared in physiological saline, so as to obtain the desired inoculum. For the wild-type strain S26, the LD50 corresponds to an inoculum of 5xl05 cfu/mouse and the LD100 corresponds to an inoculum of 1x10s cfu/mouse.
Virulence test
The mice (6-week-old Balb/c) are given an intraperitoneal injection and the bacterial solution injected represents a volume of 100 μl. Five mice are used per dose. For S26Δpg23, 4 inoculums were tested and the survival rate was measured after 24 and 48 hours post-injection. In each experiment, the study was carried out in parallel with the wild-type strain, the LD50 of which is 5xl05 cfu/mouse. The mutant S26Δpg23, injected at a dose equal to 10 times the LDioo/ causes no mortality, the mutation of the pg23 gene in the E. coli strain Kl S26 is therefore responsible for a considerable decrease in the virulence.
4 - Study of the intestinal colonization in an axenic mouse animal model
The entire experiment is carried out in a sterile environment, with sterile instruments, in an isolator, and the mice are given sterile food.
Mice These are 6- to 8-week-old axenic female mice of the C3H/He J line.
Four animals are used per bacterial strain.
Prepara tion of the inocul um
The wild-type and mutated bacteria are isolated from the strain, stored at -80°C, on an LB agar dish with or without antibiotic, and incubated at 37 °C for 18 hours. After culturing the strain in liquid medium, various dilutions are prepared in physiological saline, so as to obtain an inoculum of 107 cfu/ml.
Colonization test
The bacterial inoculation is carried out orally. During the 24 hours preceding inoculation, the mice are deprived of water. They are then given a bacterial solution at IO7 cfu/ml to drink for 4 hours. The volume of drink is measured at 0 and 4 hours, and, on average, a mouse absorbs 5 ml of this bacterial solution. The faeces are then sampled at various times, and a bacterial count is performed, taking the faeces up in physiological saline and plating out various dilutions on an LB agar dish with and without antibiotic. The results are given in table 1 herein below.
TABLE 1
Figure imgf000013_0001
For the wild-type strain S26, as well as for the mutant S26Δpg23, colonization in the intestine was stably established. No difference is observed between the wild-type strain and the mutant Δpg23. The colonization is confirmed on the final day by removing the intestine and counting the bacteria after grinding of this organ.
5 - Cloning and expression of the selected polypeptide
The nucleic acid encoding the polypeptide is cloned into a prokaryotic expression vector such as pET-14b with an N- terminal poly-his tag, according to conventional cloning methods .
The recombinant plasmid is then used to transform the E . coli strain BL21. The transformed cells are selected in the presence of ampicillin and the colonies are isolated. They are then cultured in the presence of IPTG in order to induce expression of the protein. The clones producing the protein are cultured and the total proteins are extracted by cell lysis. The recombinant protein is purified with a histidine tag affinity column, according to the manufacturer's protocol.
The protein thus obtained is purified and used in vi tro to measure its enzyme activity.
Example 2 : serum sensitivity and LD5Q determination of mutant strains in the mice model of infection
Said mutants were also compared to the wild type S26 E. coli strain for LD5o determination in the mice model of infection. As presented in Table 2 below, the number of colony forming unit (cfu) counted after culture for four hours in serum was higher in the wild type (wt) S26 strain than in mutants indicating that mutants were sensitive to serum killing.
All the different mutants were either much less virulent in mice than the wild type strain as shown by the increase in LD50
(lethal dose 50) , or completely avirulent as no dose killing 50% of mice could be reach with the mutants.
Table 2
Serum sensitivity and virulence attenuation for E . coli Kl S26 mutants in the proteins corresponding to sequence number 1 to 13
Figure imgf000015_0001
avirulent3: no dose killing 50% of mice could be reach with that mutant.
# Δlog (cfu/ml serum) = log (cfu S26wt / ml serum) - log (cfu S26 mutant / ml serum) values obtained after 4 hours in serum
* Δlog (LD50) = log (LD50 S26mutant) - log (LD50 S26wt) values obtained 48 hours after inoculation
The mutants of genes encoding the target proteins corresponding to sequences 1 to 13, which were attenuated for virulence, were still able to colonize the intestine of axenic mice as shown by persistence of bacteria in the faeces of the animals over a period of eight days. These results are presented in Table 3.
Table 3
Gut colonization for E. coli Kl S26 wt and mutants in the proteins corresponding to sequence number 1 to 13 in an axenic mouse model
Figure imgf000016_0001
* mean values based upon six experiments
The bacteria colonizing the intestine of axenic mice after eight days were characterized to verify that they correspond to the mutant strains that were inoculated orally.
The bacteria recovered from the faeces of animals had a phenotype of chloramphenicol resistance and serum sensitivity, the chloramphenicol acetyl transferase gene inserted during the mutagenesis could also be detected by PCR. Mutations in genes encoding target proteins (sequence number 1 to 13) were still present in bacteria colonizing the intestine of axenic mice as shown in Table 4.
Table 4
Characterization of bacteria recovered from axenic mice after intestinal colonization by mutants in genes encoding proteins sequence 1 to 13
Figure imgf000017_0001
# ΔLog (cfu/ml serum) = log (cfu S26wt / ml serum) - log (cfu
S26mutant / ml serum) values obtained after 4 hours in serum *The presence of the gene encoding the chloramphenicol acetyltransferase, inactivating the genes encoding the proteins of sequence number 1 to 13, has been verified by PCR and chloramphenicol resistance (CmR) .
In conclusion, the results presented in this example demonstrate that genes encoding the enzymes involved in the
LPS inner core metabolism are not essential in E . coli strains for colonization, but are necessary for resistance to complement and virulence in vivo .
They represent as such good targets for inhibitors that will selectively block bacterial replication in blood tissue.
Example 2: mutants of protein SEQ ID N°14
The present invention relates to novel mutant strain of Group B Streptococcus (GBS) { Streptococcus agalactiae) . In this particular example, the identified targets correspond to gene sequence number 29 encoding a protein sequence number 14 involved in incorporation of D-alanine residues into the cell wall-associated lipoteichoic acids (LTAs) in Gram + bacteria.
The gene sequence number 29 is homologous to the dl tD gene found in other gram positive bacteria and is the last gene of the dlt operon.
The Gram + bacterial model used is the pathogenic strain S . agalactiae NEM316. S . agalactiae is a bacterium commonly found in the human flora and is phylogeneticaly close to Gram + bacteria responsible for nosocomial septicemia.
The virulence of GBS mutants in the dlt operon is strongly impaired in mouse and newborn rat models.
Interestingly, the loss of virulence is presumably due to an increased sensitivity to antimicrobial cationic peptides, such as defensins, which are produced by numerous cells types in particular phagocytes.
The use of mutant of S . agalactiae, in which the dltD gene have been inactivated, demonstrates that the product of that gene is a good target for the development of inhibitors of virulence of S . agalactiae as well as against other Gram + pathogens. Construction of a DtlD mutant in wild type S . agalactiae NEM316:
A mutant in the dltD gene was constructed from S . agalactiae NEM316 strain by inserting, using double cross-over, a kanamycin resistance cassette.
To construct DltD mutant of S. agalactiae NEM316, a promoterless and termina torless kanamycin resistance cassette aphA-3 within DNA segment internal to dltD were inserted in the same direction of transcription . This was done by ligation after digestion wi th appropriate enzymes, of PCR products obtained by using the primers of SEQ ID N° 33 and 34 respectively,
SEQ ID N°33 : 5 ' -CAGTGAATTCGCGTTGACGAAGGCAGG-3 ' , and SEQ ID N°34 : 5 ' -GACGGGTACCATACCTATCGTAGGTTG-3 ' , and the primers of SEQ ID N° 35 and SEQ ID N°36, respectively, SEQ ID N°35 : 5 ' -AGTGGATCCACTACACAGGGCTTGATC-3 ' , and SEQ ID N°36 : 5 ' -GACCTGCAGCCCTTGATTATCCCTATCC-3 ' .
A 0.4 kb dltD EcoRI-Kpnl fragment was inserted into the thermosensitive shuttle vector pG+host5ΩaphA-3 (Biswas et al., 1993, J Bacteriol. 175:3628-3635) containing the kanamycin resistance cassette to generate pGlΩ EKaphA-3. A 0.8 kb closely spaced dltD region BamHI-Pstl fragment was inserted into pGlΩ EKaphA-3 to generate pGlΩ EKaphA-3BP. The resulting vector was introduced by electroporation into NEM316. Transformants were selected on Todd-Hewitt (TH) agar plates containing 10 mg l-1 erythromycin at 30 °C. Allelic exchange was obtained at the non-permissive temperature (42°C) by homologous recombination using a two-step procedure described previously (Biswas et al . , 1993).
A double-crossover event between the homologous sequences resulted in nucleotides deletion and insertion of the kanamycine cassette. Recombinant bacteria containing this insertion deletion were selected for kanamycine resistance. This chromosome disruption in the dltD gene was confirmed in one of the recombinant clones by sequencing the nucleotides of the mutant .
Sensitivity of the wild type S . agalactiae strain NEM316 and the DltD mutant to various antimicrobial peptides :
The sensitivity of wild type S . agalactiae NEM316 and DltD mutant to cationic antimicrobial peptides was measured by using a disk diffusion methods. The 2 strains were grown on blood agar plates and incubated for 18 hours at 37 °C. Each strain was tested using colistin (50 μg) and polymixin (10 μg) disks. Sensitivity . or resistance of NEM316 strain and the DltD mutant to each compound was determined by the size of the growth inhibition area around disk.
The DltD mutant exhibited an increased sensitivity to the cationic antimicrobial peptides colistin, and polymyxin B as shown in table 5.
Table 5
Results of sensitivity to colistin and polymixin B of control strains S. agalactiae NEM316 and DltD mutant
Figure imgf000020_0001
Study of virulence in a mouse animal model
We studied the role of DltD in the virulence of S . agalactiae. Groups of ten mice (six week-old Balb/c) were inoculated intravenously with 5 x IO7 bacteria. At 2 days post infection,
80% of mice infected with the wild type strain NEM316 died and only two deaths were recorded for mice infected with the DltD mutant. Figure 1 illustrates the results obtained with the DltD defective GBS mutant. The result demonstrates that the product of the dltD gene is necessary for virulence of GBS in mice.

Claims

1. Method for identifying and selecting a gene required for the proliferation in vivo of a pathogenic microorganism, comprising :
- using a strain of the pathogenic microorganism, - generating mutants for inactivation in the genes encoding these factors,
- determining the virulence of these mutants on an experimental model of infection, and their effect on enteric colonization in an axenic mouse model, and - selecting the bacterial genes essential for resistance to serum in vi tro, and essential, in the host, for dissemination in the serum.
2. Method according to Claim 1, characterized by the use of an E. coli strain EXPEC or a Streptococcus agalactiae strain.
3. Mutant nucleic acids for inactivation of the virulence genes as implemented in the method according to Claim 1 or 2.
4. Mutant nucleic acids which are sensitive to serum; avirulent in mice model and able to colonize gut of axenic mice.
5. Pathogenicity or virulence targets encoded by isolated or purified nucleic acids corresponding to one of the nucleotide sequences SEQ ID Nos 16-30.
6. Pathogenicity or virulence targets according to claim 5, wherein said nucleic acids correspond to one of the nucleotide sequences SEQ ID Nos 16,17,19-30.
7. Pathogenicity or virulence targets according to claim 5 or 6, wherein said nucleic acids are cDNAs .
8. Pathogenicity or virulence targets according to claim 5 or 6, wherein said nucleic acids are RNAs.
9. Pathogenicity or virulence targets according to any one of claims 6 to 8, wherein said nuclesic acids correspond to the nucleic acids of pathogenic organisms comprising Escherichia coli , Salmonella typhimurium, Klebsiella pneumoniae, Yersinia pestis , Serratia marcescens , Haemophilus influenzae, Pasteurella mul tocida , Vibrio cholerae,
Pseudomonas aeruginosa , Acetinobacter, Moraxella catarrhalis , Burkholderia pseudomallei , Neisseria meningi tidis , Neisseria gonorrhoeae, Campy loba cter j ej uni , Heli coba cter pylori , Bacteroides fragilis , Clostridium acetobutylicum ,
Mycobacteri um tuberculosis , Streptococcus pyogenes ,
Streptococcus agalactiae, Staphyloccus aureus and
Enterococcus .
10. Pathogenicity or virulence targets according to claim 9 corresponding to nucleic acids of E . coli or Streptococcus agalactiae .
11. Vectors comprising at least one pathogenicity or virulence target according to any one of claims 5 to 10.
12. Host cells containing at least one vector according to Claim 11.
13. Products of expression of the pathogenicity or virulence targets according to any one of claims 5 to 10.
14. Isolated or purified peptides characterized in that they correspond to one of the amino acid sequences SEQ ID Nos. 1 to 15.
15. Isolated or purified peptides according to claim 14 characterized in that they correspond to one of the amino acid sequences SEQ ID Nos 1,2,4-15.
16. Antibodies capable of binding specifically to the peptides according to any one of Claims 13 to 15.
17. Method for inhibiting in vi tro the proliferation of a pathogenic microorganism in serum, -comprising the use of an effective amount of a compound capable of inhibiting the activity, or of reducing the amount, of pathogenicity or virulence target according to any one of claims 6 to 10, or of inhibiting the activity of a peptide according to Claim 15.
18. Method for screening compounds capable of inhibiting the expression of the pathogenicity or virulence target according to any one of claims 6 to 10, or peptides according to claim
15, comprising bringing into contact with the test compound, demonstrating the possible effect of the compound on their activity, and selecting the active compounds.
19. Method for screening compounds capable of inhibiting the biochemical and/or enzyme activity of the peptides expressed by the pathogenicity or virulence target according to any one of claims 6 to 10.
20. Use of the compounds selected according to Claim 19, for developing medicinal products for inhibiting a bacterial infection, in particular an extra-intestinal infection in the case of enterobacteria .
PCT/EP2003/008209 2002-07-09 2003-07-09 Pathogenicity proteins which can be used as targets for developing means for preventing and controlling bacterial infections WO2004005535A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
DE60320797T DE60320797D1 (en) 2002-07-09 2003-07-09 PATHOGENIC DETERMINANTS AS TARGET MOLECULES FOR THE DEVELOPMENT OF AGENTS WHICH CAN PREVENT AND CONTROL BACTERIAL INFECTIONS AND / OR SYSTEMATIC DISSOLUTION
US10/520,820 US20060003393A1 (en) 2002-07-09 2003-07-09 Pathogenicity determinants which can be used as targets for developing means for preventing and controlling bacterial infections and/or systemic dissemination
DK03762684T DK1523572T3 (en) 2002-07-09 2003-07-09 Pathogenicity determinants that can be used as targets for developmental methods for the prevention and control of bacterial infections and / or systemic dissemination
AU2003266246A AU2003266246A1 (en) 2002-07-09 2003-07-09 Pathogenicity proteins which can be used as targets for developing means for preventing and controlling bacterial infections
EP03762684A EP1523572B1 (en) 2002-07-09 2003-07-09 Pathogenicity determinants which can be used as targets for developing means for preventing and controlling bacterial infections and/or systemic dissemination
JP2004518773A JP2006515155A (en) 2002-07-09 2003-07-09 Pathogenic determinants that can be used as targets in the development of prevention and control measures for bacterial infection and / or systemic dissemination
CA002491847A CA2491847A1 (en) 2002-07-09 2003-07-09 Pathogenicity determinants which can be used as targets for developing means for preventing and controlling bacterial infections and/or systemic dissemination
HK05109367A HK1078902A1 (en) 2002-07-09 2005-10-20 Pathogenicity determinants which can be used as targets for developing means for preventing and controlling bacterial infections and/or systemic dissemination
US11/506,821 US20070111229A1 (en) 2002-07-09 2006-08-21 Pathogenicity determinants which can be used as targets for developing means for preventing and controlling bacterial infections and/or systemic dissemination
AU2009201727A AU2009201727A1 (en) 2002-07-09 2009-04-30 Pathogenicity determinants which can be used as targets for developing means for preventing and controlling bacterial infections and/or systemic dissemination
US12/729,630 US20110236886A1 (en) 2002-07-09 2010-03-23 Pathogenicity determinants which can be used as targets for developing means for preventing and controlling bacterial infections and/or systemic dissemination

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0208636A FR2842210B1 (en) 2002-07-09 2002-07-09 PATHOGENICITY DETERMINANTS FOR USE AS TARGETS FOR PREPARING AND CONTROLLING BACTERIAL INFECTIONS AND / OR SYSTEMIC DISSEMINATION
FR0208636 2002-07-09

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/506,821 Division US20070111229A1 (en) 2002-07-09 2006-08-21 Pathogenicity determinants which can be used as targets for developing means for preventing and controlling bacterial infections and/or systemic dissemination

Publications (2)

Publication Number Publication Date
WO2004005535A2 true WO2004005535A2 (en) 2004-01-15
WO2004005535A3 WO2004005535A3 (en) 2004-11-18

Family

ID=29763685

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/008209 WO2004005535A2 (en) 2002-07-09 2003-07-09 Pathogenicity proteins which can be used as targets for developing means for preventing and controlling bacterial infections

Country Status (12)

Country Link
US (3) US20060003393A1 (en)
EP (1) EP1523572B1 (en)
JP (1) JP2006515155A (en)
AT (1) ATE394503T1 (en)
AU (2) AU2003266246A1 (en)
CA (1) CA2491847A1 (en)
DE (1) DE60320797D1 (en)
DK (1) DK1523572T3 (en)
ES (1) ES2306891T3 (en)
FR (1) FR2842210B1 (en)
HK (1) HK1078902A1 (en)
WO (1) WO2004005535A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006089264A3 (en) * 2005-02-18 2007-04-05 Novartis Vaccines & Diagnostic Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
EP2298795A1 (en) 2005-02-18 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Immunogens from uropathogenic escherichia coli
EP2586790A2 (en) 2006-08-16 2013-05-01 Novartis AG Immunogens from uropathogenic Escherichia coli
US10058600B2 (en) 2009-07-16 2018-08-28 Glaxosmithkline Biologicals Sa Detoxified Escherichia coli immunogens
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2842210B1 (en) * 2002-07-09 2012-12-14 Mutabilis PATHOGENICITY DETERMINANTS FOR USE AS TARGETS FOR PREPARING AND CONTROLLING BACTERIAL INFECTIONS AND / OR SYSTEMIC DISSEMINATION
WO2004050846A2 (en) * 2002-12-02 2004-06-17 Biosynexus Incorporated Wall teichoic acid as a target for anti-staphylococcal therapies and vaccines
EP1973467B1 (en) * 2006-01-20 2013-10-16 The General Hospital Corporation Systems and process for providing speckle reduction using a wave front modulation for optical coherence tomography
BR112018071867A2 (en) * 2016-04-25 2019-02-19 Aperture Bio Llc flow cytometer method in an automatic fluid manipulation system, flow cytometer method for testing body fluid samples, inaccuracy compensation method of flow cytometer enumeration of particles of interest in fluid samples, and automatic body fluid sample testing system
CN115725607B (en) * 2022-07-14 2023-11-28 山东第一医科大学附属省立医院(山东省立医院) Pathogenic target gene of nocardia melitensis and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999066049A2 (en) * 1998-06-12 1999-12-23 University Of Guelph A novel gene and method of treating a gram negative bacterial infection
US6020121A (en) * 1995-09-29 2000-02-01 Microcide Pharmaceuticals, Inc. Inhibitors of regulatory pathways
WO2000028038A2 (en) * 1998-11-09 2000-05-18 Microscience Limited Virulence genes and proteins, and their use
WO2000044906A2 (en) * 1999-01-27 2000-08-03 Elitra Pharmaceuticals, Inc. GENES IDENTIFIED AS REQUIRED FOR PROLIFERATION IN $i(ESCHERICHIA COLI)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2842210B1 (en) * 2002-07-09 2012-12-14 Mutabilis PATHOGENICITY DETERMINANTS FOR USE AS TARGETS FOR PREPARING AND CONTROLLING BACTERIAL INFECTIONS AND / OR SYSTEMIC DISSEMINATION

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020121A (en) * 1995-09-29 2000-02-01 Microcide Pharmaceuticals, Inc. Inhibitors of regulatory pathways
WO1999066049A2 (en) * 1998-06-12 1999-12-23 University Of Guelph A novel gene and method of treating a gram negative bacterial infection
WO2000028038A2 (en) * 1998-11-09 2000-05-18 Microscience Limited Virulence genes and proteins, and their use
WO2000044906A2 (en) * 1999-01-27 2000-08-03 Elitra Pharmaceuticals, Inc. GENES IDENTIFIED AS REQUIRED FOR PROLIFERATION IN $i(ESCHERICHIA COLI)

Non-Patent Citations (46)

* Cited by examiner, † Cited by third party
Title
ABACHIN ERIC ET AL: "Formation of D-alanyl-lipoteichoic acid is required for adhesion and virulence of Listeria monocytogenes" MOLECULAR MICROBIOLOGY, vol. 43, no. 1, January 2002 (2002-01), pages 1-14, XP002284617 ISSN: 0950-382X *
AUSTIN A E ET AL: "Genetic analysis of lipopolysaccharide core biosynthesis by Escherichia coli k12 insertion mutagenesis of the RFA locus" JOURNAL OF BACTERIOLOGY, WASHINGTON, DC, US, vol. 172, no. 9, September 1990 (1990-09), pages 5312-5325, XP000926028 ISSN: 0021-9193 *
BOYD E F & HARTL D L: "Chromosomal regions specific to pathogenic isolates of Escherichia coli have a phylogenetically clustered distribution" JOURNAL OF BACTERIOLOGY, WASHINGTON, DC, US, vol. 180, no. 5, March 1998 (1998-03), pages 1159-1165, XP002133065 ISSN: 0021-9193 *
BURNS STACY M ET AL: "Comparison of loss of serum resistance by defined lipopolysaccharide mutants and an acapsular mutant of uropathogenic Escherichia coli O75:K5." INFECTION AND IMMUNITY, vol. 66, no. 9, 1998, pages 4244-4253, XP002250632 ISSN: 0019-9567 cited in the application *
CHANG HWAN-YOU ET AL: "Virulence and outer membrane properties of a galU mutant of Klebsiella pneumoniae CG43" MICROBIAL PATHOGENESIS, vol. 20, no. 5, 1996, pages 255-261, XP002284619 ISSN: 0882-4010 *
CIESLEWICZ M ET AL: "THERMOREGULATION OF KPSF, THE FIRST REGION 1 GENE IN THE KPS LOCUS FOR POLYSIALIC ACID BIOSYNTHESIS IN ESCHERICHIA COLI K1" JOURNAL OF BACTERIOLOGY, WASHINGTON, DC, US, vol. 178, no. 11, June 1996 (1996-06), pages 3212-3220, XP000877094 ISSN: 0021-9193 *
DAINES DAYLE A ET AL: "NeuD plays a role in the synthesis of sialic acid in Escherichia coli K1" FEMS MICROBIOLOGY LETTERS, vol. 189, no. 2, 15 August 2000 (2000-08-15), pages 281-284, XP002284613 ISSN: 0378-1097 *
DATABASE GENESEQ 2 July 2002 (2002-07-02), "DLTA" XP002284651 Database accession no. ABP30484 *
DATABASE UNIPROT 1 February 1995 (1995-02-01), "KpsD" XP002284645 Database accession no. Q03961 *
DATABASE UNIPROT 1 July 1993 (1993-07-01), "GmhB" XP002284647 Database accession no. P31546 *
DATABASE UNIPROT 1 June 1994 (1994-06-01), "PGMU" XP002284644 Database accession no. P36938 *
DATABASE UNIPROT 1 March 2002 (2002-03-01), "DltD" XP002284650 Database accession no. Q8VM64 *
DATABASE UNIPROT 1 May 1992 (1992-05-01), "GalU" XP002284643 Database accession no. P25520 *
DATABASE UNIPROT 1 May 1999 (1999-05-01), "WaaC" XP002284637 Database accession no. Q9ZITI1 *
DATABASE UNIPROT 1 May 1999 (1999-05-01), "WaaO" XP002284642 Database accession no. Q9ZIS5 *
DATABASE UNIPROT 1 May 2000 (2000-05-01), "WaaG" XP002284640 Database accession no. Q9R2L8 *
DATABASE UNIPROT 1 May 2000 (2000-05-01), "WaaP" XP002284639 Database accession no. Q9R9D6 *
DATABASE UNIPROT 1 May 2000 (2000-05-01), "WaaQ" XP002284638 Database accession no. Q9R9D5 *
DATABASE UNIPROT 1 November 1990 (1990-11-01), "RFAD" XP002284648 Database accession no. P17963 *
DATABASE UNIPROT 1 November 1996 (1996-11-01), "Neud" XP002284646 Database accession no. Q46674 *
DATABASE UNIPROT 1 October 1994 (1994-10-01), "RFAF" XP002284641 Database accession no. P37692 *
DATABASE UNIPROT 15 July 1999 (1999-07-15), "rfaE" XP002284649 Database accession no. P76658 *
GENEVAUX PIERRE ET AL: "Identification of Tn10 insertions in the rfaG, rfaP, and galU genes involved in lipopolysaccharide core biosynthesis that affect Escherichia coli adhesion" ARCHIVES OF MICROBIOLOGY, vol. 172, no. 1, July 1999 (1999-07), pages 1-8, XP002284584 ISSN: 0302-8933 *
HEINRICHS DAVID E ET AL: "Molecular basis for structural diversity in the core regions of the lipopolysaccharides of Escherichia coli and Salmonella enterica." MOLECULAR MICROBIOLOGY, vol. 30, no. 2, October 1998 (1998-10), pages 221-232, XP002118873 ISSN: 0950-382X *
HONG MEI ET AL: "Effect of mutations in Shigella flexneri chromosomal and plasmid-encoded lipopolysaccharide genes on invasion and serum resistance." MOLECULAR MICROBIOLOGY, vol. 24, no. 4, 1997, pages 779-791, XP008020612 ISSN: 0950-382X *
KNEIDINGER BERND ET AL: "Biosynthesis of nucleotide-activated D-glycero-D-manno-heptose" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 24, 15 June 2001 (2001-06-15), pages 20935-20944, XP002284580 ISSN: 0021-9258 *
KNEIDINGER BERND ET AL: "Biosynthesis pathway of ADP-L-glycero-beta-D-manno-heptose in Escherichia coli" JOURNAL OF BACTERIOLOGY, vol. 184, no. 2, January 2002 (2002-01), pages 363-369, XP002284579 ISSN: 0021-9193 *
LEE N G ET AL: "Molecular cloning and characterization of the nontypable Haemophilus influenzae-2019 rfaE gene required for lipopolysaccharide biosynthesis" INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 63, no. 3, 1995, pages 818-824, XP000953326 ISSN: 0019-9567 *
MARTINDALE J ET AL: "Genetic analysisof E. Coli K1 gastrointestinal colonization" MOLECULAR MICROBIOLOGY, vol. 37, no. 6, September 2000 (2000-09), pages 1293-1305, XP002284618 ISSN: 0950-382X *
MERINO SUSANA ET AL: "Cloning and sequencing of the Klebsiella pneumoniae O5 wb gene cluster and its role in pathogenesis." INFECTION AND IMMUNITY, vol. 68, no. 5, May 2000 (2000-05), pages 2435-2440, XP002250634 ISSN: 0019-9567 *
MOXON R ET AL: "CHALLENGE OF INVESTIGATING BILOGICALLY RELEVANT FUNCTIONS OF VIRULENCE FACTORS IN BACTERIAL PATHOGENS" PHILOSOPHICAL TRANSACTIONS. ROYAL SOCIETY OF LONDON. BIOLOGICAL SCIENCES, ROYAL SOCIETY, LONDON, GB, vol. 355, no. 1397, 25 May 2000 (2000-05-25), pages 643-656, XP001007306 ISSN: 0962-8436 *
NESPER JUTTA ET AL: "Characterization of Vibrio cholerae O1 El Tor galU and galE mutants: Influence on lipopolysaccharide structure, colonization, and biofilm formation" INFECTION AND IMMUNITY, vol. 69, no. 1, January 2001 (2001-01), pages 435-445, XP002284616 ISSN: 0019-9567 *
NGELEKA MUSANGU ET AL: "Characterization of a polysaccharide capsular antigen of septicemic Escherichia coli O115: K "V165": F165 and evaluation of its role in pathogenicity" INFECTION AND IMMUNITY, vol. 60, no. 12, 1992, pages 5048-5056, XP002284585 ISSN: 0019-9567 *
RAUTEMAA RIINA ET AL: "Complement-resistance mechanisms of bacteria." MICROBES AND INFECTION, vol. 1, no. 10, August 1999 (1999-08), pages 785-794, XP002250635 ISSN: 1286-4579 cited in the application *
REGNI CATHERINE ET AL: "Crystal structure of PMM/PGM: An enzyme in the biosynthetic pathway of P. aeruginosa virulence factors" STRUCTURE (CAMBRIDGE), vol. 10, no. 2, February 2002 (2002-02), pages 269-279, XP002284620 ISSN: 0969-2126 *
RUSSO THOMAS A ET AL: "Loss of the O4 antigen moiety from the lipopolysaccharide of an extraintestinal isolate of Escherichia coli has only minor effects on serum sensitivity and virulence in vivo." INFECTION AND IMMUNITY, vol. 63, no. 4, 1995, pages 1263-1269, XP002250633 ISSN: 0019-9567 cited in the application *
See also references of EP1523572A2 *
SHEA JACQUELINE E ET AL: "Signature-tagged mutagenesis in the identification of virulence genes in pathogens." CURRENT OPINION IN MICROBIOLOGY, vol. 3, no. 5, October 2000 (2000-10), pages 451-458, XP002250636 ISSN: 1369-5274 *
SISTI FEDERICO ET AL: "In vitro and in vivo characterization of a Bordetella bronchiseptica mutant strain with a deep rough lipopolysaccharide structure" INFECTION AND IMMUNITY, vol. 70, no. 4, April 2002 (2002-04), pages 1791-1798, XP002284581 ISSN: 0019-9567 *
STOJILJKOVIC I ET AL: "CLONING AND CHARACTERIZATION OF THE NEISSERIA MENINGITIDIS RFAC GENE ENCODING ALPHA-1,5 HEPTOSYLTRANSFERASE I" FEMS MICROBIOLOGY LETTERS, AMSTERDAM, NL, vol. 151, no. 1, 1997, pages 41-49, XP001007307 ISSN: 0378-1097 *
TANG C ET AL: "PATHOGEN VIRULENCE GENES - IMPLICATIONS FOR VACCINES AND DRUG THERAPY" BRITISH MEDICAL BULLETIN, CHURCHILL LIVINGSTONE, LONDON, GB, vol. 55, no. 2, 1999, pages 387-400, XP008008098 ISSN: 0007-1420 *
VALVANO M A ET AL: "The rfaE gene from Escherichia coli encodes a bifunctional protein involved in biosynthesis of the lipopolysaccharide core precursor ADP-L-glycero-D-manno-heptose" JOURNAL OF BACTERIOLOGY, WASHINGTON, DC, US, vol. 182, no. 2, January 2000 (2000-01), pages 488-497, XP000926030 ISSN: 0021-9193 *
YETHON J A ET AL: "Involvement of waaY, waaQ and waaP in the modification of E. coli lipopolysaccharide and their role in the formation of a stable outer membrane" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 273, no. 41, 9 October 1998 (1998-10-09), pages 26310-26316, XP002118875 ISSN: 0021-9258 *
YETHON JEREMY A ET AL: "Mutation of the lipopolysaccharide core glycosyltransferase encoded by waaG destabilizes the outer membrane of Escherichia coli by interfering with core phosphorylation" JOURNAL OF BACTERIOLOGY, vol. 182, no. 19, October 2000 (2000-10), pages 5620-5623, XP002284615 ISSN: 0021-9193 *
YETHON JEREMY A ET AL: "Purification and characterization of Waap from Escherichia coli, a lipopolysaccharide kinase essential for outer membrane stability" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 8, 23 February 2001 (2001-02-23), pages 5498-5504, XP002284582 ISSN: 0021-9258 *
YETHON JEREMY A ET AL: "Salmonella enterica serovar typhimurium waaP mutants show increased susceptibility to polymyxin and loss of virulence in vivo" INFECTION AND IMMUNITY, vol. 68, no. 8, August 2000 (2000-08), pages 4485-4491, XP002284583 ISSN: 0019-9567 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006089264A3 (en) * 2005-02-18 2007-04-05 Novartis Vaccines & Diagnostic Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
EP2298795A1 (en) 2005-02-18 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Immunogens from uropathogenic escherichia coli
EP2351772A1 (en) 2005-02-18 2011-08-03 Novartis Vaccines and Diagnostics, Inc. Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli
US8758764B2 (en) 2005-02-18 2014-06-24 Novartis Vaccines And Diagnostics Srl Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli
US9334313B2 (en) 2005-02-18 2016-05-10 Glaxosmithkline Biologicals Sa Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli
US10035826B2 (en) 2005-02-18 2018-07-31 Glaxosmithkline Biologicals Sa Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli
EP2586790A2 (en) 2006-08-16 2013-05-01 Novartis AG Immunogens from uropathogenic Escherichia coli
US10058600B2 (en) 2009-07-16 2018-08-28 Glaxosmithkline Biologicals Sa Detoxified Escherichia coli immunogens
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases

Also Published As

Publication number Publication date
ES2306891T3 (en) 2008-11-16
FR2842210A1 (en) 2004-01-16
HK1078902A1 (en) 2006-03-24
JP2006515155A (en) 2006-05-25
AU2003266246A1 (en) 2004-01-23
US20110236886A1 (en) 2011-09-29
AU2009201727A1 (en) 2009-05-21
FR2842210B1 (en) 2012-12-14
WO2004005535A3 (en) 2004-11-18
US20060003393A1 (en) 2006-01-05
ATE394503T1 (en) 2008-05-15
DE60320797D1 (en) 2008-06-19
US20070111229A1 (en) 2007-05-17
EP1523572A2 (en) 2005-04-20
CA2491847A1 (en) 2004-01-15
DK1523572T3 (en) 2008-09-08
EP1523572B1 (en) 2008-05-07

Similar Documents

Publication Publication Date Title
US20110236886A1 (en) Pathogenicity determinants which can be used as targets for developing means for preventing and controlling bacterial infections and/or systemic dissemination
Timmis et al. Surface components of Escherichia coli that mediate resistance to the bactericidal activities of serum and phagocytes
Skurnik et al. A novel locus of Yersinia enterocolitica serotype O: 3 involved in lipopolysaccharide outer core biosynthesis
Keo et al. Campylobacter capsule and lipooligosaccharide confer resistance to serum and cationic antimicrobials
Jones et al. Identification of Streptococcus agalactiae virulence genes in the neonatal rat sepsis model using signature‐tagged mutagenesis
Chan et al. Contributions of two-component regulatory systems, alternative σ factors, and negative regulators to Listeria monocytogenes cold adaptation and cold growth
JP2010207227A (en) New antimicrobial polypeptide and method of use
Dentovskaya et al. Functional characterization and biological significance of Yersinia pestis lipopolysaccharide biosynthesis genes
JP2010534063A (en) Lantibiotics and their use
Zhang et al. Novel Aeromonas hydrophila PPD134/91 genes involved in O-antigen and capsule biosynthesis
US8071356B2 (en) Salmonella enterica strains of reduced pathogenicity, method for their preparation and uses thereof
CA2450658A1 (en) Essential and important genes of pseudomonas aeruginosa and the use thereof to design or identify antibacterial agents
EP2253707A2 (en) Expec-specific proteins, genes encoding them and uses thereof
Wooley et al. Analysis of plasmids cloned from a virulent avian Escherichia coli and transformed into Escherichia coli DH5α
Lemos et al. Stress responses of Streptococci
Saito et al. Fate of Legionella pneumophila in macrophages of C57BL/6 chronic granulomatous disease mice
Hallenbeck et al. The role of the universal sugar transport system components PtsI (EI) and PtsH (HPr) in Enterococcus faecium
Hoffman The Role of the Transcriptional Antiterminator RfaH in Lipopolysaccharide Synthesis, Resistance to Antimicrobial Peptides, and Virulence of Yersinia Pseudotuberculosis and Yersinia Pestis
Chatzidaki Relationship of the Vibrio vulnificus group 1-like capsular polysaccharide operon to phase variation
Vivo efa1/Citrobacter rodentium lifA
Walker Molecular characterization of IS1223 and localization of the insertion element to strategic positions in the genome of Lactobacillus johnsonii
Shippy et al. Characterization of SEN3800-associated virulence of Salmonella enterica serovar Enteritidis phage type 8
WO2003089572A2 (en) Essential and important genes of pseudomonas aeroginosa and the use thereof to design or identify antibacterial agents
Hamilton et al. In Vivo Gene Expression Analysis Identifies
by Macrophages et al. Revised manuscript (IAI05693-11)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003266246

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2491847

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004518773

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003762684

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003762684

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006003393

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10520820

Country of ref document: US

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 10520820

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2003762684

Country of ref document: EP